Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00574366 · ClinicalTrials.gov registry record · Phase 1

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

A Phase 1 study of Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
3
Study locations

NCT00574366: Completed Phase 1 study of Breast Cancer, sponsored by Vanderbilt-Ingram Cancer Center.

NCT00574366 is a Phase 1 study of Breast Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 14 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00574366, a Phase 1 study of Breast Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
3
Study locations

Study Summary

RATIONALE: Erlotinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving erlotinib together with everolimus and to see how well it works in treating patients with metastatic breast cancer.

Primary Outcome

MTD will be the dose level at which fewer than 2 of 6 (or 33% of) patients experience dose limiting toxicity (DLT), starting at first 4 weeks.

Conditions Studied

Breast Cancer

Interventions

  • DRUG RAD001
  • DRUG erlotinib

Study Locations (3)

Tennessee

  • Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
  • Vanderbilt-Ingram Cancer Center at Franklin - Nashville
  • Vanderbilt-Ingram Cancer Center - Nashville

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2005-12
Est. Completion 2009-02
Phase Phase 1
Vanderbilt-Ingram Cancer Center

189 total trials

What the finished NCT00574366 record still lists

NCT00574366 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which RAD001 is the first listed.

NCT00574366 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT00574366 about?

NCT00574366 is a clinical study titled "Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer". RATIONALE: Erlotinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib together with everolimus may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving erlotinib together ...

What is the current status of trial NCT00574366?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-12. Estimated completion is 2009-02.

What conditions does trial NCT00574366 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00574366?

The interventions under investigation include: RAD001 (DRUG), erlotinib (DRUG).

Who is sponsoring clinical trial NCT00574366?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00574366 being conducted?

This trial has 3 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00574366's enrollment target sits among peer trials

14 1154th of 1224 higher than 65 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00574366, the US trial registry maintained by the National Library of Medicine. NCT00574366 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.